NexImmune, Inc. Common Stock

NexImmune, Inc. Common Stock

Compare this stock

NEXI Stock Report Card

$

VolatilityTechnicalsProfitPerformanceEarnings

25%

Performance

Score:

10/100

NEXI returned -75.26% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

Score:

25/100

NEXI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

Score:

49/100

NEXI has missed earnings 2 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 15 quarters, NEXI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

38/100

NEXI has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

NexImmune, Inc. Common Stock Summary

Nasdaq / NEXI
Healthcare
Biotechnology
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.